Clinical Trial Update: Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing apremilast to placebo for mild-to-moderate plaque psoriasis. Safety and efficacy results were posted in May 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-05-17